Reneo Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(77,388) | $(51,955) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 5,112 | 4,320 |
| Depreciation and amortization | 170 | 88 |
| Amortization/accretion on short-term investments | (4,777) | (817) |
| Changes in the fair value of performance award | (22) | (415) |
| Non-cash lease expense | 355 | 441 |
| Right-of-use and leasehold improvement impairment expenses | 650 | 17 |
| Changes in operating assets and liabilities: | ||
| Prepaid and other assets | 1,524 | 878 |
| Accounts payable and accrued expenses | 11,118 | 518 |
| Operating lease liabilities | (424) | (437) |
| Net cash used in operating activities | (63,682) | (47,362) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (221) | (346) |
| Purchase of available-for-sale short-term investments | (231,257) | (101,596) |
| Proceeds from maturities of available-for-sale short-term investments | 242,000 | 44,100 |
| Net cash provided by (used in) investing activities | 10,522 | (57,842) |
| Cash flows from financing activities | ||
| Proceeds from public offering of common stock, net of offering costs | 58,862 | — |
| Proceeds from private placement of common stock, net of offering costs | 4,667 | 193 |
| Repurchase of common stock in connection with common stock repurchase agreement | (4,403) | — |
| Proceeds from issuance of common stock under the at-the-market facility, net of offering costs | 1,009 | — |
| Proceeds from issuance of common stock in connection with equity plans | 730 | 278 |
| Net cash provided by financing activities | 60,865 | 471 |
| Net increase (decrease) in cash and cash equivalents | 7,705 | (104,733) |
| Cash and cash equivalents, beginning of year | 19,927 | 124,660 |
| Cash and cash equivalents, end of year | $27,632 | $19,927 |
| Noncash operating activities: | ||
| Right-of-use assets obtained in exchange for lease obligations | $— | $1,733 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.